Price Chart

DATE TIME TYPE PERIOD REPORTED
EPS
ESTIMATED
EPS
SURPRISE
11/04/2022* -- Results Q3 2022 -- 0.84 --
11/04/2022* 08:00 EST Earnings Call Q3 2022 -- -- --
08/04/2022 -- Results Q2 2022 0.89 0.70 26.69%
08/04/2022 08:00 EST Earnings Call Q2 2022 -- -- --
04/29/2022 -- Results Q1 2022 0.97 0.46 110.9%
04/29/2022 08:00 EST Earnings Call Q1 2022 -- -- --
02/24/2022 -- Results Q4 2021 0.25 0.17 50.00%
02/24/2022 08:00 EST Earnings Call Q4 2021 -- -- --
*Estimated Date/Time

Earnings

Next Report Date 11/04/2022 (est.)
EPS Estimate Upgrade
Last Actual EPS Upgrade

Loading chart...
Last Report Date 08/04/2022
Beat/Miss Upgrade
Return Since 4.86%
Last FQE 06/30/2022
Next FQE 09/30/2022

Profile

Edit
Lantheus Holdings Inc caters to the United States healthcare sector with the development of diagnostic products. Its imaging products and agents assist clinicians in the diagnosis and treatment of cardiovascular and other diseases. Its agents are typically non-radioactive compounds that are used in diagnostic procedures, such as cardiac ultrasounds, or echocardiograms, x-ray imaging used by physicians to progress the clarity of the diagnostic image. Its portfolio of imaging products includes medical radiopharmaceuticals such as DEFINITY, TechneLite, Xenon Xe 133 Gas, Cardiolite, and Neurolite. Its revenue is generated from the sales of diagnostic imaging agents to wholesalers, distributors radiopharmacy and directly to hospitals and clinics predominantly in the United States.
URL http://www.lantheus.com
Investor Relations URL https://investor.lantheus.com
HQ State/Province Massachusetts
Sector Healthcare
Industry Drug Manufacturers - Specialty & Generic
Equity Style Small Cap/Growth
Next Earnings Release Nov. 04, 2022 (est.)
Last Earnings Release Aug. 04, 2022
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Dividends

Dividend Per Share (TTM) --
2017
2018
2019
2020
2021
No data available
 
6.00%
4.00%
2.00%
 
Yield to Market 0.00
Yield to Sector 0.00
Yield to Industry 0.00
Last Dividend Amt. --
Dividend Frequency --
Last Ex-Dividend Date --
Yield (TTM) 0%
Forward Yield --
Payout Ratio 0.00%
Cash Payout Ratio 0.00%
Consistent Payer (5Y) No
Consistent Growth (5Y) No

Ownership

Insider Ownership Percentage Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Short Interest

Short Interest Upgrade
Percent of Shares Outstanding Short Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Total Returns Comparison

Edit comparables

Annual Total Returns Versus Peers

Edit comparables
Loading chart...
Name
2015
2016
2017
2018
2019
2020
2021
YTD
--
154.4%
137.8%
-23.47%
31.05%
-34.23%
114.2%
158.6%
1.38%
11.96%
21.83%
-4.38%
31.49%
18.40%
28.71%
-20.46%
--
--
--
--
--
136.2%
71.93%
56.55%
--
-55.30%
172.3%
4.32%
93.64%
-45.52%
-32.42%
134.0%
--
--
--
--
--
--
--
--
--
--
--
--
--
--
4.56%
-17.32%
As of October 06, 2022.

Profile

Edit
Lantheus Holdings Inc caters to the United States healthcare sector with the development of diagnostic products. Its imaging products and agents assist clinicians in the diagnosis and treatment of cardiovascular and other diseases. Its agents are typically non-radioactive compounds that are used in diagnostic procedures, such as cardiac ultrasounds, or echocardiograms, x-ray imaging used by physicians to progress the clarity of the diagnostic image. Its portfolio of imaging products includes medical radiopharmaceuticals such as DEFINITY, TechneLite, Xenon Xe 133 Gas, Cardiolite, and Neurolite. Its revenue is generated from the sales of diagnostic imaging agents to wholesalers, distributors radiopharmacy and directly to hospitals and clinics predominantly in the United States.
URL http://www.lantheus.com
Investor Relations URL https://investor.lantheus.com
HQ State/Province Massachusetts
Sector Healthcare
Industry Drug Manufacturers - Specialty & Generic
Equity Style Small Cap/Growth
Next Earnings Release Nov. 04, 2022 (est.)
Last Earnings Release Aug. 04, 2022
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Ownership

Insider Ownership Percentage Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Short Interest

Short Interest Upgrade
Percent of Shares Outstanding Short Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Top Fund Holders

Symbol Dollars Invested % Weight
DYN004 90.35M USD 4.76%
HRSRX 39.97M USD 3.89%
LADSX 79.32M USD 2.90%
QUARX 65.97M USD 1.56%
CHCIX 42.01M USD 1.48%
SLYG 16.65M USD 0.79%
IJT 37.69M USD 0.78%
SPSM 25.80M USD 0.63%
IJR 373.56M USD 0.62%
VIOO 24.49M USD 0.61%
VTSIX 47.86M USD 0.59%
IWO 39.17M USD 0.44%

Top Portfolio Holders

0 of 0

Other Resources

Whale Wisdom 13F Filings
Seeking Alpha Call Transcripts
Morningstar Insider Trading
Nasdaq Institutional Ownership
Nasdaq Option Chain
SEC SEC Filings
Twitter LNTH Tweets